Jayshree Shriram Dawane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jayshree Shriram Dawane has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Priti Dhande
Bharati Vidyapeeth Deemed University
4 shared publications Kaushal Navanath Mehetre
Department of Pharmacology, Bharati Vidyapeeth (Deemed to be University) Medical College
2 shared publicationsPriti Dhande
Department of Pharmacology, Bharati Vidyapeeth University Medical College
2 shared publicationsAishwarya Dhakne
Department of Pharmacology, Bharati Vidyapeeth University Medical College
1 shared publication- Asmita Wele
Department of Rasashastra Bhaishajyakalpana, Dr. D. Y. Patil College of Ayurved and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to be University), Pune, 411018, India
1 shared publication - Bharati Avinash Dalal
Department of Microbiology, Bharati Vidyapeeth DU Medical College, Pune, Maharashtra, India
1 shared publication
Latest Publications
- Open Access
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1933913
Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives
Obesity is a long-term, complex disorder characterised by excessive adiposity that increases the risk of metabolic and cardiovascular diseases. Obesity is a significant health problem, with its prevalence increasing steadily over the last several decades. This rising trend has contributed substantially to the burden of metabolic, cardiovascular and other chronic diseases. Lifestyle modification remains the primary approach to obesity treatment; long-term weight reduction is difficult to achieve and sustain due to complex neurohormonal mechanisms that regulate appetite and energy homeostasis. Consequently, pharmacotherapy has become an essential component of comprehensive obesity management in appropriately selected patients. Recent advances in obesity pharmacology have revolutionised treatment strategies, particularly with the introduction of incretin-based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, which have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss. Furthermore, several novel agents, including triple agonists, oral peptide formulations, and combination therapies, are currently undergoing clinical evaluation and are expected to further transform obesity treatment. This review provides the current understanding of obesity pharmacotherapy, discusses approved anti-obesity medications, highlights emerging therapeutic agents and drugs under clinical development, and explores future perspectives in obesity management. Additionally, the review addresses current challenges, safety concerns, and public health strategies required to combat the growing obesity epidemic.
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1933913
Open AccessAdvances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives
Obesity is a long-term, complex disorder characterised by excessive adiposity that increases the risk of metabolic and cardiovascular diseases. Obesity is a significant health problem, with its prevalence increasing steadily over the last several decades. This rising trend has contributed substantially to the burden of metabolic, cardiovascular and other chronic diseases. Lifestyle modification remains the primary approach to obesity treatment; long-term weight reduction is difficult to achieve and sustain due to complex neurohormonal mechanisms that regulate appetite and energy homeostasis. Consequently, pharmacotherapy has become an essential component of comprehensive obesity management in appropriately selected patients. Recent advances in obesity pharmacology have revolutionised treatment strategies, particularly with the introduction of incretin-based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, which have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss. Furthermore, several novel agents, including triple agonists, oral peptide formulations, and combination therapies, are currently undergoing clinical evaluation and are expected to further transform obesity treatment. This review provides the current understanding of obesity pharmacotherapy, discusses approved anti-obesity medications, highlights emerging therapeutic agents and drugs under clinical development, and explores future perspectives in obesity management. Additionally, the review addresses current challenges, safety concerns, and public health strategies required to combat the growing obesity epidemic.
- Open Access
- 12 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1901723
A comparative study of the impact of prescription and non-prescription mucolytic agents on respiratory disease management in a community-based population
Introduction: Respiratory disease significantly impacts quality of life at the same time economic burden. Mucolytic agents are widely used in respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and upper respiratory tract infections (URTIs). However, real-world differences in clinical outcomes between prescription-guided and over-the-counter (OTC) mucolytic use in community settings remain inadequately characterized. Objective: The present study aimed to compare symptom improvement and adverse effects between prescription based and OTC mucolytic users, and to evaluate patterns of usage and healthcare seeking behaviour consultation in a community setting. Methods: A longitudinal observational study conducted among 200 participants categorized into OTC and prescription groups conducted after getting institutional Ethical approval (BVDUMC/IEC/399/25-26). Data collected using structured questionnaires assessing symptom scores, adverse effects, and healthcare utilization. Statistical analysis included descriptive statistics and Chi-square test. A p value of p < 0.01). Prescription-based therapy was associated with better symptom control, appropriate drug selection, and adherence to recommended dosing regimens. Conversely, OTC use was characterized by inconsistent dosing, inappropriate drug selection, and suboptimal therapeutic outcomes. The incidence of adverse drug reactions was slightly higher in the Prescription group, predominantly gastrointestinal in nature. Furthermore, awareness regarding appropriate indications, dosage, and duration of mucolytic therapy was significantly lower among OTC users. Conclusion: Prescription mucolytic therapy demonstrated better outcomes compared to OTC use, likely due to structured treatment and medical supervision. These findings indicate the importance of rational prescribing and patient education in respiratory disease management.
- 12 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1901723
Open AccessA comparative study of the impact of prescription and non-prescription mucolytic agents on respiratory disease management in a community-based population
Introduction: Respiratory disease significantly impacts quality of life at the same time economic burden. Mucolytic agents are widely used in respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and upper respiratory tract infections (URTIs). However, real-world differences in clinical outcomes between prescription-guided and over-the-counter (OTC) mucolytic use in community settings remain inadequately characterized. Objective: The present study aimed to compare symptom improvement and adverse effects between prescription based and OTC mucolytic users, and to evaluate patterns of usage and healthcare seeking behaviour consultation in a community setting. Methods: A longitudinal observational study conducted among 200 participants categorized into OTC and prescription groups conducted after getting institutional Ethical approval (BVDUMC/IEC/399/25-26). Data collected using structured questionnaires assessing symptom scores, adverse effects, and healthcare utilization. Statistical analysis included descriptive statistics and Chi-square test. A p value of p < 0.01). Prescription-based therapy was associated with better symptom control, appropriate drug selection, and adherence to recommended dosing regimens. Conversely, OTC use was characterized by inconsistent dosing, inappropriate drug selection, and suboptimal therapeutic outcomes. The incidence of adverse drug reactions was slightly higher in the Prescription group, predominantly gastrointestinal in nature. Furthermore, awareness regarding appropriate indications, dosage, and duration of mucolytic therapy was significantly lower among OTC users. Conclusion: Prescription mucolytic therapy demonstrated better outcomes compared to OTC use, likely due to structured treatment and medical supervision. These findings indicate the importance of rational prescribing and patient education in respiratory disease management.
- Open Access
- 31 March 2026
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 39 (1) , 53
Comparative study of Valsartan and Leucovorin alone or in combination for renal protection in methotrexate-induced acute kidney injury in rats
Methotrexate (MTX) is a widely used chemotherapeutic and immunosuppressive agent that may induce acute kidney injury (AKI), posing a major clinical challenge. This study investigated the renoprotective effects of Valsartan, Leucovorin and their combination in mitigating methotrexate (MTX)-induced renal damage in Wistar rats. The aim was to evaluate these effects in a rat model of MTX-induced acute kidney injury (AKI). After approval by the Institutional Animal Ethics Committee (IAEC), forty male Wistar rats were divided into five groups: control (saline), MTX (single intraperitoneal injection of 20 mg/kg), Valsartan (10 mg/kg/day), leucovorin (10 mg/kg/day), and combination (Valsartan plus leucovorin). Drug treatment was initiated one day before MTX administration and continued orally for five days. Renal function was assessed by measuring serum creatinine and blood urea nitrogen (BUN). Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were evaluated as inflammatory markers, while malondialdehyde (MDA) and glutathione (GSH) were assessed as oxidative stress markers. Histopathological examination of renal tissue was also performed. Data were analyzed using GraphPad Prism version 6. The MTX group showed significant renal dysfunction (p < 0.001) and increased inflammatory and oxidative stress markers. Both Valsartan and leucovorin produced partial renoprotective effects, with Valsartan significantly reducing oxidative stress (p < 0.001) and leucovorin markedly decreasing inflammatory markers (p < 0.001). The combination therapy demonstrated the most pronounced renoprotective effect (p < 0.001), as evidenced by improved renal function and reduced oxidative damage and inflammation. Histopathological analysis revealed decreased tubular necrosis and inflammatory infiltration in the combination group. Valsartan and leucovorin exerted individual renoprotective effects; however, their combined administration provided highly significant protection against MTX-induced AKI. These findings suggest that combination therapy may represent a promising strategy for preventing renal injury in patients undergoing MTX treatment.
- 31 March 2026
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 39 (1) , 53
Open AccessComparative study of Valsartan and Leucovorin alone or in combination for renal protection in methotrexate-induced acute kidney injury in rats
Methotrexate (MTX) is a widely used chemotherapeutic and immunosuppressive agent that may induce acute kidney injury (AKI), posing a major clinical challenge. This study investigated the renoprotective effects of Valsartan, Leucovorin and their combination in mitigating methotrexate (MTX)-induced renal damage in Wistar rats. The aim was to evaluate these effects in a rat model of MTX-induced acute kidney injury (AKI). After approval by the Institutional Animal Ethics Committee (IAEC), forty male Wistar rats were divided into five groups: control (saline), MTX (single intraperitoneal injection of 20 mg/kg), Valsartan (10 mg/kg/day), leucovorin (10 mg/kg/day), and combination (Valsartan plus leucovorin). Drug treatment was initiated one day before MTX administration and continued orally for five days. Renal function was assessed by measuring serum creatinine and blood urea nitrogen (BUN). Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were evaluated as inflammatory markers, while malondialdehyde (MDA) and glutathione (GSH) were assessed as oxidative stress markers. Histopathological examination of renal tissue was also performed. Data were analyzed using GraphPad Prism version 6. The MTX group showed significant renal dysfunction (p < 0.001) and increased inflammatory and oxidative stress markers. Both Valsartan and leucovorin produced partial renoprotective effects, with Valsartan significantly reducing oxidative stress (p < 0.001) and leucovorin markedly decreasing inflammatory markers (p < 0.001). The combination therapy demonstrated the most pronounced renoprotective effect (p < 0.001), as evidenced by improved renal function and reduced oxidative damage and inflammation. Histopathological analysis revealed decreased tubular necrosis and inflammatory infiltration in the combination group. Valsartan and leucovorin exerted individual renoprotective effects; however, their combined administration provided highly significant protection against MTX-induced AKI. These findings suggest that combination therapy may represent a promising strategy for preventing renal injury in patients undergoing MTX treatment.
- Open Access
- 3 March 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1765648
Evaluation of potential of Revstone® on gentamicin-induced renal toxicity in Wistar rats: a comparative study of the capsule and syrup forms
Introduction: Revstone ®, a polyherbal formulation available in capsule and syrup forms, is designed to treat kidney-related disorders. However, its renoprotective efficacy remains insufficiently validated. In this study, we aimed to evaluate and compare the renoprotective potential of Revstone ® capsule and syrup formylations in Wistar rats. Objective: The aim of this study was to assess the acute toxicity profile of Revstone ® capsule and syrup following Organisation for Economic Co-operation and Development (OECD) guidelines and compare their efficacy in reversing renal damage based on biochemical, histological, and functional markers. Methodology: Acute oral toxicity testing was conducted according to the OECD 423 guidelines, and rats were observed for 14 days for mortality, behavioural and clinical changes, body weight variations, and gross necropsy findings. For efficacy evaluation, nephrotoxicity was induced by gentamicin (80 mg/kg i.p. for 7 days). Rats were divided into seven groups, namely, the normal control, disease control, Revstone ® syrup (low and high dose), Revstone ® capsule (low and high dose), and standard drug control (valsartan 10 mg/kg). Renal function was assessed from serum creatinine, blood urea nitrogen, and uric acid levels. Oxidative stress markers such as malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT) were measured, and histopathological evaluation of kidney tissue was performed. Data were analysed using one-way ANOVA followed by Tukey’s post hoc test ( p < 0.05). Results: Gentamicin significantly elevated renal markers ( p < 0.001). Revstone ® syrup at high dose markedly reduced creatinine ( p < 0.001), while both formulations improved oxidative stress and renal histology. The syrup formulation was more effective, indicating its potential for future clinical application. Conclusion: Revstone ® capsule and syrup demonstrated significant renoprotective activities in gentamicin-induced nephrotoxicity in rats.
- 3 March 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1765648
Open AccessEvaluation of potential of Revstone® on gentamicin-induced renal toxicity in Wistar rats: a comparative study of the capsule and syrup forms
Introduction: Revstone ®, a polyherbal formulation available in capsule and syrup forms, is designed to treat kidney-related disorders. However, its renoprotective efficacy remains insufficiently validated. In this study, we aimed to evaluate and compare the renoprotective potential of Revstone ® capsule and syrup formylations in Wistar rats. Objective: The aim of this study was to assess the acute toxicity profile of Revstone ® capsule and syrup following Organisation for Economic Co-operation and Development (OECD) guidelines and compare their efficacy in reversing renal damage based on biochemical, histological, and functional markers. Methodology: Acute oral toxicity testing was conducted according to the OECD 423 guidelines, and rats were observed for 14 days for mortality, behavioural and clinical changes, body weight variations, and gross necropsy findings. For efficacy evaluation, nephrotoxicity was induced by gentamicin (80 mg/kg i.p. for 7 days). Rats were divided into seven groups, namely, the normal control, disease control, Revstone ® syrup (low and high dose), Revstone ® capsule (low and high dose), and standard drug control (valsartan 10 mg/kg). Renal function was assessed from serum creatinine, blood urea nitrogen, and uric acid levels. Oxidative stress markers such as malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT) were measured, and histopathological evaluation of kidney tissue was performed. Data were analysed using one-way ANOVA followed by Tukey’s post hoc test ( p < 0.05). Results: Gentamicin significantly elevated renal markers ( p < 0.001). Revstone ® syrup at high dose markedly reduced creatinine ( p < 0.001), while both formulations improved oxidative stress and renal histology. The syrup formulation was more effective, indicating its potential for future clinical application. Conclusion: Revstone ® capsule and syrup demonstrated significant renoprotective activities in gentamicin-induced nephrotoxicity in rats.
- Open Access
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 2791
Evaluation of Hemostatic and In vitro Antimicrobial Activity of (Revalum®) Feracrylum Gel
The study aims to evaluate the haemostatic and in vitro antimicrobial activity of Feracrylum gel Revalum ®, a novel topical formulation designed for wound management. An assessment was done to determine the haemostatic efficacy of the Feracrylum gel through standardized clotting assays, measuring its ability to promote bleeding control in both in-vitro and in-vivo models. The antimicrobial efficacy of the gel was assessed by testing its activity against a range of bacterial strains, encompassing both Gram-positive and Gram-negative bacteria, using the disk diffusion technique. The Feracrylum gel (Revalum) ® demonstrated significant hemostatic properties, with a marked reduction in bleeding time (p<0.05) and clotting time (p<0.001) compared to control treatments. In antimicrobial assays, the gel exhibited moderate antimicrobial activity against Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus with 12mm, 10mm and 5mm zone of inhibition respectively. Feracrylum gel (Revalum) ® shows promising potential as an effective hemostatic agent and the gel demonstrates significant antimicrobial activity, indicating its potential for effective use in clinical wound care. Additional research is needed to evaluate its long-term efficacy and safety across various wound management scenarios.
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 2791
Open AccessEvaluation of Hemostatic and In vitro Antimicrobial Activity of (Revalum®) Feracrylum Gel
The study aims to evaluate the haemostatic and in vitro antimicrobial activity of Feracrylum gel Revalum ®, a novel topical formulation designed for wound management. An assessment was done to determine the haemostatic efficacy of the Feracrylum gel through standardized clotting assays, measuring its ability to promote bleeding control in both in-vitro and in-vivo models. The antimicrobial efficacy of the gel was assessed by testing its activity against a range of bacterial strains, encompassing both Gram-positive and Gram-negative bacteria, using the disk diffusion technique. The Feracrylum gel (Revalum) ® demonstrated significant hemostatic properties, with a marked reduction in bleeding time (p<0.05) and clotting time (p<0.001) compared to control treatments. In antimicrobial assays, the gel exhibited moderate antimicrobial activity against Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus with 12mm, 10mm and 5mm zone of inhibition respectively. Feracrylum gel (Revalum) ® shows promising potential as an effective hemostatic agent and the gel demonstrates significant antimicrobial activity, indicating its potential for effective use in clinical wound care. Additional research is needed to evaluate its long-term efficacy and safety across various wound management scenarios.
- Open Access
- 31 December 2024
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 29 (4) , 414-421
Evaluation of the Anxiolytic and Antidepressant Effects of Standardized Ashwagandha (Withania somnifera) Root Extract in Wistar Rats
Jayshree Dawane, Sanghee Seok, Priti Dhande, Deepak Langade, Hwana Han, Sang-Back Kim, and Jae-Yeong Ju. Prev Nutr Food Sci 2024;29:414-21. https://doi.org/10.3746/pnf.2024.29.4.414
- 31 December 2024
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 29 (4) , 414-421
Open AccessEvaluation of the Anxiolytic and Antidepressant Effects of Standardized Ashwagandha (Withania somnifera) Root Extract in Wistar Rats
Jayshree Dawane, Sanghee Seok, Priti Dhande, Deepak Langade, Hwana Han, Sang-Back Kim, and Jae-Yeong Ju. Prev Nutr Food Sci 2024;29:414-21. https://doi.org/10.3746/pnf.2024.29.4.414
- Open Access
- 30 November 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (6) , 100980
Toxicity profile of standardized Krishna Vajra Abhraka bhasma made from biotite mica
- 30 November 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (6) , 100980
Open AccessToxicity profile of standardized Krishna Vajra Abhraka bhasma made from biotite mica
- Open Access
- 30 September 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (3) , 1595-1602
Study the Effect of Drakshasava on Dopamine, Serotonin and Cortisol Levels and Behavioural Changes in Acute and Chronic Stress Model in Wistar Rats
Drakshasava is a formulation used as a general tonic also for anxiety, anaemia in the Ayurveda. Our previous study reports for antidepressant property were very promising. This study aims to elucidate the antidepressant mechanisms of Drakshasava by examining its effects on key neurotransmitters and stress hormones, as well as observing related behavioral changes in Wistar rats under stress models. Methods: Wistar rats weighing 150-200 gms were divided into six groups consisting of 6 rats in each group. Two animal models, acute stress (AS) and unpredictable chronic mild stress (UCMS) were used. Drug treatment was given as per groups orally, Drakshasava in the dose of 2ml & 4ml/kg and Fluoxetine standard comparator 10mg/kg for next 7 days for AS. In UCMS group stress was given for 15 days and drug treatment was given along with the stress from day 15-21. Sucrose preference test (SPT) done on day 0 & 8 in AS and on day 0, 15, 22 in UCMS model rats and at the end Forced Swim test (FST) was performed. Blood withdrawal done for estimation of serum Dopamine, Serotonin and cortisol levels with ELISA kit on day 8 in AS & 22 in UCMS. Data obtained analysed with Graph Pad Prism 6. Result: Decrease in Dopamine (p<0.05) and Serotonin (p<0.01) while increase (p<0.01) in cortisol levels was seen in (depressed) disease control group rats in comparison with control group. Both doses of Drakshasava showed significant reduction in immobility time in FST and improved sucrose preference and was found to be effective in both the models of depression. Increase in serum serotonin (p<0.01) and dopamine (p<0.05) levels was evident while at the same time, (p<0.05) cortisol level reduction was seen in all drug treated rats. Findings observed in the FST and SPT were correlated with the biochemical findings. Effects seen with Drakshasava were comparable with that of Fluoxetine. Conclusion: Drakshasava increased serum serotonin and dopamine levels while decreasing cortisol levels in both acute and chronic animal models of depression. These effects were comparable to those observed with the standard antidepressant drug, Fluoxetine.
- 30 September 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (3) , 1595-1602
Open AccessStudy the Effect of Drakshasava on Dopamine, Serotonin and Cortisol Levels and Behavioural Changes in Acute and Chronic Stress Model in Wistar Rats
Drakshasava is a formulation used as a general tonic also for anxiety, anaemia in the Ayurveda. Our previous study reports for antidepressant property were very promising. This study aims to elucidate the antidepressant mechanisms of Drakshasava by examining its effects on key neurotransmitters and stress hormones, as well as observing related behavioral changes in Wistar rats under stress models. Methods: Wistar rats weighing 150-200 gms were divided into six groups consisting of 6 rats in each group. Two animal models, acute stress (AS) and unpredictable chronic mild stress (UCMS) were used. Drug treatment was given as per groups orally, Drakshasava in the dose of 2ml & 4ml/kg and Fluoxetine standard comparator 10mg/kg for next 7 days for AS. In UCMS group stress was given for 15 days and drug treatment was given along with the stress from day 15-21. Sucrose preference test (SPT) done on day 0 & 8 in AS and on day 0, 15, 22 in UCMS model rats and at the end Forced Swim test (FST) was performed. Blood withdrawal done for estimation of serum Dopamine, Serotonin and cortisol levels with ELISA kit on day 8 in AS & 22 in UCMS. Data obtained analysed with Graph Pad Prism 6. Result: Decrease in Dopamine (p<0.05) and Serotonin (p<0.01) while increase (p<0.01) in cortisol levels was seen in (depressed) disease control group rats in comparison with control group. Both doses of Drakshasava showed significant reduction in immobility time in FST and improved sucrose preference and was found to be effective in both the models of depression. Increase in serum serotonin (p<0.01) and dopamine (p<0.05) levels was evident while at the same time, (p<0.05) cortisol level reduction was seen in all drug treated rats. Findings observed in the FST and SPT were correlated with the biochemical findings. Effects seen with Drakshasava were comparable with that of Fluoxetine. Conclusion: Drakshasava increased serum serotonin and dopamine levels while decreasing cortisol levels in both acute and chronic animal models of depression. These effects were comparable to those observed with the standard antidepressant drug, Fluoxetine.
- Open Access
- 1 January 2024
- Published by Medknow in Asian Journal of Pharmaceutical Research and Health Care
- Vol. 16 (1) , 91-95
Comparison of Antimicrobials Used for Surgical Prophylaxis in Obstetrics and Gynecology Department of Ayurveda and Modern Medicine
Introduction: Antimicrobial prophylaxis is essential during cesarean section since the risk of infection is high. Some complications are encountered during the surgery such as surgical site infections (SSIs), endometritis, and urinary tract infection. Different antimicrobial agents (AMAs) are used for prophylaxis in allopathy and Ayurveda. The present study was planned to find out the pattern of usage of antimicrobials in women undergoing cesarean section from both systems of medicine. Methodology: A prospective, observational, cross-sectional, unicentric, descriptive study was conducted during the period of June 2022 to September 2022. Women undergone lower segment cesarean section (LSCS) from allopathy and Ayurveda, department of gynecology and obstetrics were included in the study. Information about demographic details, antibiotic used with duration, number, generic or branded, details about wound healing and SSIs was recorded. Results: Cefuroxime and metronidazole were the most commonly prescribed AMAs. From the total participants, 44% were below the age of 25 years and 50% were primigravida. Thirty-four percentage women were undergone elective LSCS whereas 66% were emergency LSCS because of various indications. All the drugs were prescribed with band names. No SSI was observed in the patients of both systems of medicine. All the patients from the Ayurveda received the AMAs along with other Ayurvedic medicines. Conclusion: Preoperative prophylaxis was given to all the patients at the right time. No infection was observed in all the patients. However, compared with the duration of treatment, Ayurvedic patients received antimicrobials for longer duration which needs attention.
- 1 January 2024
- Published by Medknow in Asian Journal of Pharmaceutical Research and Health Care
- Vol. 16 (1) , 91-95
Open AccessComparison of Antimicrobials Used for Surgical Prophylaxis in Obstetrics and Gynecology Department of Ayurveda and Modern Medicine
Introduction: Antimicrobial prophylaxis is essential during cesarean section since the risk of infection is high. Some complications are encountered during the surgery such as surgical site infections (SSIs), endometritis, and urinary tract infection. Different antimicrobial agents (AMAs) are used for prophylaxis in allopathy and Ayurveda. The present study was planned to find out the pattern of usage of antimicrobials in women undergoing cesarean section from both systems of medicine. Methodology: A prospective, observational, cross-sectional, unicentric, descriptive study was conducted during the period of June 2022 to September 2022. Women undergone lower segment cesarean section (LSCS) from allopathy and Ayurveda, department of gynecology and obstetrics were included in the study. Information about demographic details, antibiotic used with duration, number, generic or branded, details about wound healing and SSIs was recorded. Results: Cefuroxime and metronidazole were the most commonly prescribed AMAs. From the total participants, 44% were below the age of 25 years and 50% were primigravida. Thirty-four percentage women were undergone elective LSCS whereas 66% were emergency LSCS because of various indications. All the drugs were prescribed with band names. No SSI was observed in the patients of both systems of medicine. All the patients from the Ayurveda received the AMAs along with other Ayurvedic medicines. Conclusion: Preoperative prophylaxis was given to all the patients at the right time. No infection was observed in all the patients. However, compared with the duration of treatment, Ayurvedic patients received antimicrobials for longer duration which needs attention.
- Open Access
- 20 October 2023
- Published by Elsevier in Toxicology Reports
- Vol. 11, 389-395
Sub-acute toxicity of Ashwagandha (Withania somnifera) root extract in wistar rats
- 20 October 2023
- Published by Elsevier in Toxicology Reports
- Vol. 11, 389-395
Open AccessSub-acute toxicity of Ashwagandha (Withania somnifera) root extract in wistar rats